177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 2, 2011, Pages 312-322

  Seidl, Christof ^a   Zöckler, Christine ^a   Beck, Roswitha ^a   Quintanilla Martinez, Leticia ^b   Bruchertseifer, Frank ^c   Senekowitsch Schmidtke, Reingard ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c JOINT RESEARCH CENTRE   (Italy)

Author keywords

Emitter 213Bi; Emitter 177Lu; Disseminated gastric carcinoma; Locoregional radioimmunotherapy; Toxicity

Indexed keywords

ANTIBODY CONJUGATE; BISMUTH 213; LUTETIUM 177; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY D8 LU 177; MONOCLONAL ANTIBODY D9 LU 177; UNCLASSIFIED DRUG; UVOMORULIN; BISMUTH; LUTETIUM; RADIOISOTOPE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; BLOOD CELL COUNT; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LYMPHOBLASTOMA; MOUSE; NONHUMAN; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIOIMMUNOTHERAPY; STOMACH CANCER; SURVIVAL TIME; TUMOR CELL; ANIMAL; BLOOD; CHEMISTRY; COMPARATIVE STUDY; DISEASE MODEL; DRUG STABILITY; METABOLISM; METHODOLOGY; PATHOLOGY; PERITONEUM TUMOR; RADIATION DOSE; STOMACH TUMOR; TIME; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; BISMUTH; BLOOD CELL COUNT; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG STABILITY; FEMALE; HUMANS; IMMUNOCONJUGATES; LUTETIUM; MICE; PERITONEAL NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOTHERAPY DOSAGE; STOMACH NEOPLASMS; TIME FACTORS;

EID: 79551513604     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1639-2     Document Type: Article

References (41)

1. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 74 108 10.3322/canjclin.55.2.74 15761078
2. R Rosenberg H Nekarda P Bauer U Schenck H Hoefler JR Siewert 2006 Free peritoneal tumour cells are an independent prognostic factor in curatively resected stage IB gastric carcinoma Br J Surg 93 325 331 1:STN:280: DC%2BD287ivVGqsQ%3D%3D 10.1002/bjs.5196 16498603
3. EP Jansen H Boot M Verheij CJ van de Velde 2005 Optimal locoregional treatment in gastric cancer J Clin Oncol 23 4509 4517 10.1200/JCO.2005.21.196 16002841 (Pubitemid 46196580)
4. FA Khan AN Shukla 2006 Pathogenesis and treatment of gastric carcinoma: "an up-date with brief review" J Cancer Res Ther 2 196 199 1:CAS:528:DC%2BD2sXjtlenu70%3D 10.4103/0973-1482.29830 17998703
5. S Yamagata B Nakata K Hirakawa 2004 Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may be effective against peritoneal dissemination in gastric cancer Oncol Rep 12 973 978 1:CAS:528: DC%2BD2cXhtVWksLrP 15492780
6. D Cunningham WH Allum SP Stenning JN Thompson CJ Van de Velde M Nicolson, et al. 2006 Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 11 20 1:CAS:528:DC%2BD28Xms1Chsrw%3D 10.1056/NEJMoa055531 16822992
7. L Lim M Michael GB Mann T Leong 2005 Adjuvant therapy in gastric cancer J Clin Oncol 23 6220 6232 1:CAS:528:DC%2BD2MXhtVKgtbrI 10.1200/JCO.2005.11.593 16135489
8. B Illert C Otto HP Vollmers F Hensel A Thiede W Timmermann 2005 Human antibody SC-1 reduces disseminated tumor cells in nude mice with human gastric cancer Oncol Rep 13 765 770 1:CAS:528:DC%2BD2MXjtFansbY%3D 15756455
9. A Ohtsu 2008 Chemotherapy for metastatic gastric cancer: past, present, and future J Gastroenterol 43 256 264 1:CAS:528:DC%2BD1cXlsVOntrc%3D 10.1007/s00535-008-2177-6 18458840 (Pubitemid 351650035)
10. G Berx KF Becker H Höfler F van Roy 1998 Mutations of the human E-cadherin (CDH1) gene Hum Mutat 12 226 237 1:CAS:528:DyaK1cXmtFWqsr8%3D 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D 9744472 (Pubitemid 28418891)
11. KF Becker E Kremmer M Eulitz I Becker G Handschuh C Schuhmacher, et al. 1999 Analysis of E-cadherin in diffuse-type gastric cancer using a mutation-specific monoclonal antibody Am J Pathol 155 1803 1809 1:CAS:528:DC%2BD3cXit1Kiug%3D%3D 10595908
12. 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer Cancer Res 61 2804 2808 1:CAS:528:DC%2BD3MXivFGrur8%3D 11306447
13. 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death Eur J Nucl Med Mol Imaging 32 274 285 1:CAS:528:DC%2BD2MXis1ajt7Y%3D 10.1007/s00259-004- 1653-3 15791436 (Pubitemid 40562118)
14. 213Bi-induced death of HSC45-M2 gastric cancer cells is characterized by G2 arrest and up-regulation of genes known to prevent apoptosis but induce necrosis and mitotic catastrophe Mol Cancer Ther 6 2346 2359 1:CAS:528:DC%2BD2sXptVGlurs%3D 10.1158/1535-7163.MCT-07-0132 17699730 (Pubitemid 47294763)
15. C Seidl M Port C Apostolidis F Bruchertseifer M Schwaiger R Senekowitsch-Schmidtke, et al. 2010 Differential gene expression triggered by highly cytotoxic alpha-emitter-immunoconjugates in gastric cancer cells Invest New Drugs 28 49 60 1:CAS:528:DC%2BC3cXjslOmtw%3D%3D 10.1007/s10637-008-9214-4 19139817
16. R Huber C Seidl E Schmid S Seidenschwang KF Becker C Schuhmacher, et al. 2003 Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody Clin Cancer Res 9 Pt 2 3922s 3928s 1:CAS:528:DC%2BD3sXosVOksbw%3D 14506190
17. 213Bi-radioimmunotherapy using bioluminescence imaging Eur J Nucl Med Mol Imaging 34 841 849 10.1007/s00259-006-0311-3 17206415 (Pubitemid 46798953)
18. 213Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude mice Cancer Sci 98 1215 1222 1:CAS:528:DC%2BD2sXosV2ltb4%3D 10.1111/j.1349-7006.2007.00525.x 17561973 (Pubitemid 46994574)
19. 213Bi-radioimmunoconjugates in vitro and in vivo following intraperitoneal dissemination Curr Radiopharm 1 215 224 1:CAS:528:DC%2BD1MXlt1Oqtbc%3D 10.2174/1874471010801030215
20. 177Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin J Nucl Med 45 1224 1232 1:CAS:528:DC%2BD2cXnsFygsb0%3D 15235070
21. 177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts Cancer Res 67 326 331 1:CAS:528: DC%2BD2sXisFSrsA%3D%3D 10.1158/0008-5472.CAN-06-2363 17210714 (Pubitemid 46142791)
22. 177Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival J Clin Oncol 26 2124 2130 1:CAS:528:DC%2BD1cXms1Ort7s%3D 10.1200/JCO.2007.15.2553 18445841
23. K Yanagihara A Ito T Toge M Numoto 1993 Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract Cancer Res 53 5815 5821 1:CAS:528:DyaK2cXpsV2mug%3D%3D 8242641
24. Y Fukudome K Yanagihara M Takeichi F Ito S Shibamoto 2000 Characterization of a mutant E-cadherin protein encoded by a mutant gene frequently seen in diffuse-type human gastric carcinoma Int J Cancer 88 579 583 1:CAS:528:DC%2BD3cXotVKit78%3D 10.1002/1097-0215(20001115)88:4<579::AID- IJC10>3.0.CO;2-U 11058874
25. KF Becker E Kremmer M Eulitz S Schulz J Mages G Handschuh, et al. 2002 Functional allelic loss detected at the protein level in archival human tumours using allele-specific E-cadherin monoclonal antibodies J Pathol 197 567 574 1:CAS:528:DC%2BD38Xntlekuro%3D 10.1002/path.1149 12210074
26. 177Lu for radioimmunotherapeutic applications Nucl Med Biol 29 431 442 1:CAS:528:DC%2BD38XjvVWjurw%3D 10.1016/S0969-8051(02)00294-9 12031878 (Pubitemid 34597115)
27. TK Nikula MJ Curcio MW Brechbiel OA Gansow RD Finn DA Scheinberg 1995 A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies Nucl Med Biol 22 387 390 1:CAS:528:DyaK2MXlvFGlsL0%3D 10.1016/0969-8051(94)00126-5 7627155
28. 213Bi-conjugated monoclonal antibody Clin Cancer Res 11 7070s 7074s 1:CAS:528:DC%2BD2MXhtVKiurnM 10.1158/1078-0432.CCR-1004-0017 16203804 (Pubitemid 41428706)
29. 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC J Nucl Med 46 1310 1316 1:CAS:528:DC%2BD28XitVGlsLc%3D 16085587
30. M van Essen EP Krenning BL Kam M de Jong R Valkema DJ Kwekkeboom 2009 Peptide-receptor radionuclide therapy for endocrine tumors Nat Rev Endocrinol 5 382 393 10.1038/nrendo.2009.105 19488074
31. 177Lu-DOTATATE: the role of associated risk factors Eur J Nucl Med Mol Imaging 35 1847 1856 1:CAS:528: DC%2BD1cXhtFCjtbzP 10.1007/s00259-008-0778-1 18427807
32. 177Lu-DOTA0, Tyr3]octreotate Eur J Nucl Med Mol Imaging 34 763 771 1:CAS:528:DC%2BD2sXks1agsLk%3D 10.1007/s00259-006-0291-3 17146655 (Pubitemid 46669362)
33. EJ Rolleman BF Bernard WA Breeman F Forrer E de Blois J Hoppin, et al. 2008 Molecular imaging of reduced renal uptake of radiolabelled [DOTA0, Tyr3]octreotate by the combination of lysine and Gelofusine in rats Nuklearmedizin 47 110 115 1:CAS:528:DC%2BD1cXotFalu7w%3D 18493690
34. L Mårtensson R Nilsson T Ohlsson HO Sjögren SE Strand J Tennvall 2007 Reduced myelotoxicity with sustained tumor concentration of radioimmunoconjugates in rats after extracorporeal depletion J Nucl Med 48 269 276 17268025
35. F Aarts T Hendriks A Eek WJ Oyen RP Bleichrodt OC Boerman 2009 Can antibody galactosylation be used to improve radioimmunotherapy of induced peritoneal carcinomatosis of colonic origin in the rat? Cancer Biother Radiopharm 24 29 34 1:CAS:528:DC%2BD1MXisVSrtLg%3D 10.1089/cbr.2008.0521 19243245
36. 177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo Nucl Med Biol 32 269 278 1:CAS:528:DC%2BD2MXjtV2isrc%3D 10.1016/j.nucmedbio.2005.01.003 15820762 (Pubitemid 40488384)
37. 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy Prostate 69 92 104 1:CAS:528:DC%2BD1MXhsFCns7o%3D 10.1002/pros.20856 18942092
38. 177Lu- labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity Clin Cancer Res 11 Pt 2 7195s 7200s 1:CAS:528:DC%2BD2MXhtVKiurbL 10.1158/1078-0432.CCR-1004-0023 16203821 (Pubitemid 41428723)
39. 177Lu-CC49: a phase I/II study Gynecol Oncol 65 94 101 1:CAS:528:DyaK2sXivFKjsrc%3D 10.1006/gyno.1996.4577 9103398 (Pubitemid 27171559)
40. RF Meredith DJ Buchsbaum RD Alvarez AF LoBuglio 2007 Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer Clin Cancer Res 13 Pt 2 5643s 5645s 1:CAS:528:DC%2BD2sXhtVCitLvJ 10.1158/1078-0432.CCR-07-0985 17875801 (Pubitemid 47510398)
41. F Aarts MJ Koppe T Hendriks JE van Eerd WJ Oyen OC Boerman, et al. 2007 Timing of adjuvant radioimmunotherapy after cytoreductive surgery in experimental peritoneal carcinomatosis of colorectal origin Ann Surg Oncol 14 533 540 10.1245/s10434-006-9247-x 17122992 (Pubitemid 46175298)